Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson’s disease are dependent on frontal function-Reference-Cited by-同舟云学术

Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson’s disease are dependent on frontal function

Published:2022-11-15 Issue:3 Volume:44 Page:913-918
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Murakami Hidetomo^ORCID,Okumura Motohiro,Ozawa Masakazu,Mimori Masahiro,Maku Takahiro,Shiraishi Tomotaka,Kitagawa Tomomichi,Takatsu Hiroki,Sato Takeo,Komatsu Teppei,Sakai Kenichiro,Umehara Tadashi,Omoto Shusaku,Mitsumura Hidetaka,Iguchi Yasuyuki

Funder

Ministry of Education, Culture, Sports, Science, and Technology

Jikei University Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-022-06499-6.pdf

Reference32 articles.

1. PD Med Collaborative Group, Gray R, Ives N et al (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384(9949):1196–1205. https://doi.org/10.1016/S0140-6736(14)60683-8

2. Jankovic J, Poewe W (2012) Therapies in Parkinson’s disease. Curr Opin Neurol 25(4):433–447. https://doi.org/10.1097/WCO.0b013e3283542fc2

3. Pålhagen S, Heinonen EH, Hägglund J et al (1998) Selegiline delays the onset of disability in de novo parkinsonian patients. Swed Parkins Study Group Neurol 51(2):520–525. https://doi.org/10.1212/wnl.51.2.520

4. Murakami H, Nohara T, Uchiyama M et al (2017) Accumulation of 123I-ioflupane is a useful marker of the efficacy of selegiline monotherapy in drug-naïve Parkinson’s disease. Front Aging Neurosci 9:321. https://doi.org/10.3389/fnagi.2017.00321

5. Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9(12):1200–1213. https://doi.org/10.1016/S1474-4422(10)70212-X